FINWIRES · TerminalLIVE
FINWIRES

$HOWL

3 stories mentioning HOWLUpdated 33d ago

Every FINWIRES story that references HOWL, newest first.

What's the latest news on HOWL?

Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) gained 1.8%.In corporate news, Johnson & Johnson (JNJ) shares rose 1.3% after the firm said Friday Tecvayli plus daratumumab has been approved by the European Commission to treat adults with relapsed or refractory multiple myeloma.Arbutus Biopharma (ABUS) shares jumped past 7% after the firm said it plans to launch a tender offer to repurchase up to $230 million of its shares at between $5.00 and $5.75 per share.Gossamer Bio (GOSS) shares were up 0.8% after the firm said it has agreed to sell up to $250 million of securities in a structured private placement to new and existing institutional investors.Werewolf Therapeutics (HOWL) and Ambros Therapeutics said they have struck an all-stock merger agreement to create a late-stage biotech company. Werewolf shares surged 108%.

$ABUS$GOSS$HOWL$JNJ
Sectors

Sector Update: Healthcare Stocks Edge Higher Pre-Bell Friday

Healthcare stocks were edging higher pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Arbutus Biopharma (ABUS) shares were up more than 9% after the clinical-stage company said it plans to launch a modified Dutch auction tender offer to repurchase up to $230 million of its common shares at between $5 and $5.75 per share in cash.Aveanna Healthcare Holdings (AVAH) said selling stockholders priced a secondary public offering of 15 million common shares at $11.75 per share. Aveanna Healthcare stock was down nearly 3% premarket.Werewolf Therapeutics (HOWL) and Ambros Therapeutics entered into an all-stock merger agreement to create a Nasdaq-listed biotech focused on developing neridronate for complex regional pain syndrome type 1, the companies said. Shares of Werewolf were up 146% pre-bell.

$ABUS$AVAH$HOWL$IBB$XLV
Insider Trading

Werewolf Therapeutics Insider Sold Shares Worth $280,210, According to a Recent SEC Filing

Luke Evnin, Director, on May 08, 2026, sold 407,574 shares in Werewolf Therapeutics (HOWL) for $280,210. Following the Form 4 filing with the SEC, Evnin has control over a total of 1,171,175 common shares of the company, with 1,171,175 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1785530/000113465726000010/xslF345X05/form4-05122026_110537.xml

$HOWL

Track with the FINWIRES app suite